FibroBiologics
Houston, Texas, United States · Biotechnology, Health Care, Therapeutics · 15 employees
FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics,
Funding history
- Seed · $500K · Sep 2026
- Seed · $3.0M · Jun 2026
- Seed · $1.7M · Dec 2025
- Seed · $1.5M · Dec 2025
- Seed · $4.0M · Dec 2025
Recent signals
- Sep 17, 2026: SEC 8-K (5.01): On September 17, 2026, FibroBiologics, Inc. conducted a Special Meeting of Stockholders where significant proposals were voted on, including the approval of the issuance of up to 8,163,266 shares of common stock tied to outstanding warrants. The meeting saw participation from shareholders representing 3,431,761 of the total 8,283,193 eligible votes, demonstrating active involvement in corporate governance. The vote was held pursuant to Section 14(a) of the Securities Exchange Act, and no opposition was noted against the solicitation by the Board. The strategic implications of these approvals could impact the company's financial leverage and shareholder value moving forward.
- Sep 16, 2026: Raised $500K in Seed
- Sep 15, 2026: SEC 8-K (1.01): On September 15, 2026, FibroBiologics, Inc. entered into a securities purchase agreement (SPA) with Dr. Hamid Khoja, the Company’s Chief Scientific Officer. Under this agreement, the Company will sell 298,508 shares of its common stock along with warrants to purchase an equal number of shares in a private placement. The shares and warrants are issued at an offering price of $1.675 each, which includes a premium over the previous day's closing bid price of $1.55. The expected gross proceeds from this transaction are approximately $0.5 million, which will support the company's operations and strategic growth initiatives.
- Aug 24, 2026: Leigh Steinberg Appointed as Class II Director at FibroBiologics
- Aug 20, 2026: SEC 8-K (5.02): On August 20, 2026, FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of the Board, effective immediately. He will serve until the 2028 annual meeting of stockholders. Mr. Steinberg's compensation will align with the other non-employee directors according to the Company's Non-Employee Director Compensation Policy. Importantly, there are no disclosed transactions or arrangements requiring further regulatory disclosure linked to Mr. Steinberg's appointment. This strategic move signifies a continued focus on strong governance and leadership within the organization.
- Jun 29, 2026: Raised $3.0M in Seed
- Dec 16, 2025: Raised $1.7M in Seed
- Dec 03, 2025: Raised $1.5M in Seed
See plans & pricing → Track FibroBiologics’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches FibroBiologics across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.